Reducing mortality in newly diagnosed standard-risk acute promyelocytic leukemia in elderly patients treated with arsenic trioxide requires major reduction of chemotherapy: a report by the French Belgian Swiss APL group (APL 2006 trial).

Details

Request a copyRequest a copy
Serval ID
serval:BIB_9ECB1E4E3ADF
Type
Article: article from journal or magazin.
Collection
Publications
Institution
UNIL/CHUV
Title
Reducing mortality in newly diagnosed standard-risk acute promyelocytic leukemia in elderly patients treated with arsenic trioxide requires major reduction of chemotherapy: a report by the French Belgian Swiss APL group (APL 2006 trial).
Journal
Haematologica
Author(s)
Rahmé R., Ades L., Thomas X., Guerci-Bresler A., Pigneux A., Vey N., Raffoux E., Castaigne S., Spertini O., Wittnebel S., Marolleau J.P., Damaj G., Bordessoule D., Lejeune J., Chevret S., Fenaux P.
ISSN
1592-8721 (Electronic)
ISSN-L
0390-6078
Publication state
Published
Issued date
11/2018
Peer-reviewed
Oui
Volume
103
Number
11
Pages
e519-e521
Language
english
Notes
Publication types: Clinical Trial ; Letter ; Multicenter Study ; Research Support, Non-U.S. Gov't
Publication Status: ppublish
Keywords
Aged, Aged, 80 and over, Arsenic Trioxide/administration & dosage, Arsenic Trioxide/adverse effects, Disease-Free Survival, Female, Humans, Leukemia, Promyelocytic, Acute/diagnosis, Leukemia, Promyelocytic, Acute/drug therapy, Leukemia, Promyelocytic, Acute/mortality, Male, Survival Rate
OAI-PMH
oai:serval.unil.ch:BIB_9ECB1E4E3ADF
DOI
10.3324/haematol.2018.193151
Pubmed
29794147
Web of science
000451732200006
Open Access
Yes
Create date
31/05/2018 19:01
Last modification date
14/10/2019 6:09
Usage data